Mms Holdings
Mms Holdings is recorded as a service provider in 19 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 19 of 19 trials · Latest update first
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease
Sponsor Tectonic Operating Company Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
Sponsor Kardigan Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra pulmonary Involvement
Sponsor Xentria Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
Sponsor C4 Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathy
Sponsor Longboard Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Sponsor Elion Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications
Sponsor Cerevance Beta Inc.
- Start (EU)
- Latest update
- Estimated end
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
Sponsor Neumora Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
B7981032 - A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Sponsor Immunome Inc.
- Start (EU)
- Latest update
- Estimated end
A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations
Sponsor Xentria Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants with Major Depressive Disorder
Sponsor Neumora Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)
Sponsor Marinus Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations
Sponsor Xentria Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Mms Holdings?
The 2026-10-09 snapshot links Mms Holdings to 19 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Statistical analysis, Data management, Medical writing, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Mms Holdings?
The most frequently recorded therapeutic areas are Cardiology, Neurology, Respiratory, Haematological Malignancies. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Mms Holdings conducted?
The linked trials record locations in 19 countries, including Spain, Poland, Italy, Germany, Czechia. These are trial locations, not confirmed office locations or countries where Mms Holdings delivered services.
What can this page tell me about Mms Holdings's trial experience?
Browse 19 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Mms Holdings. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Mms Holdings Inc.